Reduced residual renal function is associated with endothelial dysfunction in patients receiving peritoneal dialysis

Peritoneal Dialysis International

Volumn 32, Issue 2, 2012, Pages 149-158

  Han, Seung Hyeok ^a   Lee, Sang Choel ^b   Kang, Ea Wha ^c   Park, Jung Kyung ^a   Yoon, Hyang Sook ^d   Yoo, Tae Hyun ^a   Choi, Kyu Hun ^a   Han, Dae Suk ^a   Kang, Shin Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c National Health Insurance Corporation   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Endothelial dysfunction; Residual renal function

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; UREA;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPEREMIA; ISCHEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PULSE PRESSURE; TREATMENT DURATION; VASODILATATION;

ADULT; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; VASCULAR DISEASES;

EID: 84863229645     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00111     Document Type: Article

References (37)

1. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38(4 Suppl):S26-S29.
2. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15:454-457.
3. Wang AY. Vascular and other tissue calcification in peritoneal dialysis patients. Perit Dial Int 2009; 29(Suppl 2): S9-S14.
4. Joannides R, Haefeli WE, Linder L, Richard V, Bak-kali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
6. van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13:1782-1786.
7. Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M, Moore N, et al. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997; 12:2623-2628.
8. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004; 65:700-4.
9. Bargman JM, Golper TA. The importance of residual renal function for patients on dialysis. Nephrol Dial Transplant 2005; 20:671-673.
10. Wang AY. The "heart" of peritoneal dialysis. Perit Dial Int 2007; 27(Suppl 2):S228-S232.
11. Ghiadoni L, Cupisti A, Huang Y, Mattei P, Cardinal H, Favilla S, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004; 17:512-519.
12. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 2001; 59:1834-18341.
13. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-1251.
14. van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J am Soc Nephrol 1996; 7:745-750.
15. NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1):S65-S136.
16. Pride ET, Gustafson J, Graham A, Spainhour L, Mauck V, Brown P, et al. Comparison of a 2.5% and a 4.25% dextrose peritoneal equilibration test. Perit Dial Int 2002; 22: 365-370.
17. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Char-bonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J am Coll Cardiol 2002; 39:257-265.
18. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005; 20:396-403.
19. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003; 18: 892-898.
20. Jacobson SH, Egberg N, Hylander B, Lundahl J. Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002; 22:42-47.
21. Annuk M, Lind L, Linde T, Fellstrom B. Impaired endothe-lium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 2001; 16:302-306.
22. Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, et al. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005; 45:715-729.
23. Huang WH, Chen KH, Hsu CW, Chen YC, Hung CC, Huang JY, et al. Residual renal function-one of the factors associated with arterial stiffness in peritoneal dialysis patients. Insight from a retrospective study in 146 peritoneal dialysis patients. Blood Purif 2008; 26:133-137.
24. Cheng LT, Gao YL, Qin C, Tian JP, Gu Y, Bi SH, et al. Volume overhydration is related to endothelial dysfunction in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2008; 28:397-402.
25. Menon MK, naimark DM, Bargman JM, Vas SI, Oreopou-los DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16:2207-2213.
26. Lameire N, Van Biesen W. Importance of blood pressure and volume control in peritoneal dialysis patients. Perit Dial Int 2001; 21:206-11.
27. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J am Soc Nephrol 2004; 15:2186-2194.
28. Stompor T, Zdzienicka A, Motyka M, Dembinska-Kiec A, Davies SJ, Sulowicz W. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int 2002; 22: 670-676.
29. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-9165.
30. Vanhoutte PM, Shimokawa HH, Tang EH, Feletou M. En-dothelial dysfunction and vascular disease. Acta Physiol (oxf) 2009; 196:193-222.
31. Costopoulos C, Liew TV, Bennett M. Ageing and atherosclerosis: mechanisms and therapeutic options. Biochem Pharmacol 2008; 75:1251-1261.
32. Jensen-Urstad K, Johansson J. Gender difference in age-related changes in vascular function. J Intern Med 2001; 250:29-36.
33. Wang AY, Lai Kn. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69:1726-1732.
34. Zhe XW, Tian XK, Chen W, Guo LJ, Gu Y, Chen HM, et al. Association between arterial stiffness and peritoneal small solute transport rate. Artif organs 2008; 32:416-419.
35. Figueiredo AE, Pinheiro da Costa BE, Conti A, Poitevin AA, Filho BJ, Torres E, et al. Peritoneal transport function and endothelium-dependent vasodilation. Perit Dial Int 2007; 27:203-205.
36. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation 2007; 115:2373-2375.
37. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38:85-90.